Refining adverse drug reaction signals by incorporating interaction
  variables identified using emergent pattern mining by Reps, Jenna M. et al.
 Refining adverse drug reaction signals by 
incorporating interaction variables identified using 
emergent pattern mining 
Jenna M. Repsa, Uwe Aickelina, Richard B. Hubbardb 
aSchool of Computer Science, Jubilee Campus, University of Nottingham, NG8 1BB bSchool of 
Medicine, University of Nottingham, Nottingham, NG5 1PB 
 
Abstract 
Purpose: To develop a framework for identifying and incorporating 
candidate confounding interaction terms into a regularised cox regression 
analysis to refine adverse drug reaction signals obtained via longitudinal 
observational data. 
Methods: We considered six drug families that are commonly associated 
with myocardial infarction in observational healthcare data, but where the 
causal relationship ground truth is known (adverse drug reaction or not). 
We applied emergent pattern mining to find itemsets of drugs and medical 
events that are associated with the development of myocardial infarction. 
These are the candidate confounding interaction terms. We then 
implemented a cohort study design using regularised cox regression that 
incorporated and accounted for the candidate confounding interaction 
terms. 
Results The methodology was able to account for signals generated due to 
confounding and a cox regression with elastic net regularisation correctly 
ranked the drug families known to be true adverse drug reactions above 
those 
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that are not. This was not the case without the inclusion of the candidate 
confounding interaction terms, where confounding leads to a non-adverse 
drug reaction being ranked highest. 
Conclusions The methodology is efficient, can identify high-order 
confounding interactions and does not require expert input to specify 
outcome specific confounders, so it can be applied for any outcome of 
interest to quickly refine its signals. The proposed method shows excellent 
potential to overcome some forms of confounding and therefore reduce the 
false positive rate for signal analysis using longitudinal data. 
Keywords: Medical Informatics, signal refinement, data mining, 
observational data, confounding, emergent pattern mining 
 
1. Introduction 
Negative side effects of medication, termed adverse drug reactions 
(ADRs), are a serious burden to healthcare ??. ADRs are estimated as the 
cause of 6.5% of UK hospitalisations ? and a study investigating US death due 
to ADRs reported rates between 0.08-0.12 per 100,000 ?. Studies have 
suggested that the rate of ADRs is increasing annually ?, motivating the 
improvement of methods for detecting them. 
The process of detecting ADRs starts during clinical trials, however 
clinical trials often lack sufficient power to detect all ADRs for numerous 
reasons including time limitations, unrealistic conditions and a limited 
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number of people being included ?. It is then down to post-marketing 
surveillance to identify the remaining undiscovered ADRs. This involves 
three stages: signal detection (identifying associations between drugs and 
outcomes), signal refinement (prioritising/filtering spurious relationships) 
and signal evaluation (confirming causality after numerous sources of 
evidence). There has been a big focus towards developing signal detection 
methods, involving various forms of data such as spontaneous reporting 
systems ?, online data ??, chemical structures ? and longitudinal 
observational data ??. Unfortunately, all the data sources have their own 
limitations. Spontaneous reporting systems are historically the main source 
used for post-marketing analysis but often contain missing values, suffer 
from under- and over-reporting, and rely on people noticing ADRs ?. 
Longitudinal observational data have recently been used to complement 
spontaneous reporting system data for extracting new drug safety 
information, and are an excellent potential source of information due to the 
quantity of observational data available and the number of variables 
recorded. If we could overcome existing issues, mainly confounding, that 
limit the use of observational data for causal inference then we may be able 
to aid the discovery of new ADRs. 
We are often plagued with confounding when investigating potential 
causal relationships retrospectively in observational data ? due to the data 
collection being non-random. When an association between an exposure and 
outcome is discovered in observational data, it may often be explained by the 
presence of confounding. A confounding variable is one that leads to distorted 
effect estimates between an exposure and outcome due to the confounder 
being associated with both the exposure and outcome. For a variable to be 
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considered a confounder of an exposure and outcome relationship it must be 
a risk factor of the outcome, it must be associated with the exposure and it 
can not lie within the causal pathway between the exposure and outcome. 
Consider, for example, the situation where we wish to determine the 
relationship between a drug given to treat hypertension and myocardial 
infarction. If we naively look at the incidence of myocardial infarction within 
a year after treatment for patients given the drug and the incidence of 
myocardial infarction within a randomly chosen year for patients never 
given the drug, then we are likely to find that myocardial infarction is more 
common in those given the drug and conclude that the drug is associated 
with an increased incidence of myocardial infarction. However, our 
conclusion is likely explained by confounding, as patients given the drug 
(those with hypertension) are medically different from those who do not 
have hypertension. It is likely that some of the patients given the drug have 
a poor diet or are stressed. Poor diet and stress would have contributed to 
the hypertension but are also risk factors of myocardial infarction. Therefore 
poor diet and stress would be confounding factors. To correctly determine a 
relationship between an exposure and outcome it is important to account for 
confounding variables. Techniques such as risk adjustment, stratification, or 
equally distributing the confounding variables between the comparison 
groups are potential ways to reduce confounding ?. 
Adjusting for confounders in observational data requires identifying the 
confounders. Although existing methods aim to address confounding, 
various studies have shown that existing signal generation methods 
developed for longitudinal observational data have a high false positive rate 
??. This is most likely due to difficulties identifying confounding variables in 
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a data-driven way. Some studies have shown that including a large number 
of variables, such as drug indications, into drug safety methods can reduce 
confounding ???, but none of these methods included interactive terms. A 
medical illness is likely to be a result of multiple variables interacting. For 
example, cardiovascular disease is common in patients with a genetic 
predisposition such as familial hypercholesterolemia and based on lifestyle 
such as diet and exercise. Therefore, it is interactive terms between medical 
events or drugs that are most likely to correspond to confounding variables. 
However, when there are thousands of medical events and drugs, the 
number of possible interactions is very large. Existing data-driven methods 
for incorporating interactive terms into regression models include 
hierarchal lasso, which adds the interactions along with an interaction 
regularisation term ?, and methods utilising matrix factorisation ?. However, 
these methods are likely to be highly inefficient when there are thousands of 
variables to consider (which is often the case for observational data). 
Instead, methods such as emergent pattern mining ? that can efficient 
identify outcome specific associations, even when large numbers of 
variables are being considered, may be more suitable. A similar idea was 
used to successfully detect survival associate rules ? based on cox regression 
and association rule mining. This shows that it is possible to reduce 
confounding by combining cox regression and association rule mining. 
A suitable post-marketing framework that extracts knowledge from 
longitudinal observational data could be of the form displayed in Figure 1. 
The first stage of the proposed framework is to apply an efficient large-scale 
signal generation method to find associations between exposures and 
outcomes. In the first step the method would efficiently search through all 
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the exposure and outcome possibilities to find associated pairs. An example 
of a suitable signal generation method is the high dimensionality propensity 
score 
  
Figure 1: Overview of the methodology. Our proposed data-driven signal refinement is 
applied to ADR signals generated elsewhere to prioritize/filter them before formal evalu6 
ation. It will filter some signals that can be explained by confounding and prioritizes the 
remaining signals ready for evaluation. 
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(HDPS) ?. The HDPS works by developing a predictive model for taking the 
drug and then a matched cohort analysis is applied, where controls are 
selected based on having a high propensity for taking the drug (the predictive 
model predicts that they would have the drug). The HDPS can limit 
confounding by accounting for a large number of variables. Unfortunately, it 
is not without issues ?? and still often signals many false positives ?, this 
highlights the requirement of additional analysis that can reduce the false 
positive rate. The second step in the framework is the signal refinement, 
where complex confounding relationships are discovered and incorporated 
into a more detailed analysis. The output of the signal refinement is a small 
set of exposure-outcome pairs that are prioritized for signal evaluation. The 
final step would be to formally evaluate the remaining signals using a 
number of different data sources, as establishing a causal relationship 
requires an accumulation of evidence. 
In this paper we focus on the signal refinement stage, as there are no data-
driven methods to refine signals, but numerous signal generation and 
evaluation methods exist. The objective of this research is to develop a data-
driven signal refinement methodology that can be applied after ADR signal 
generation using longitudinal observational data to filter and re-rank the 
signals by addressing complex confounding. We will test the data-driven 
methodology by analysing the relationship between numerous drugs and the 
outcome myocardial infarction (MI). We are exploring three goals: 
1. Whether emergent pattern mining can be used to identify candidate 
interaction confounding covariates in a data-driven way. 
2. Whether the inclusion of interaction confounding covariates into a 
regression analysis can reduce confounding and be used for data-
driven ADR signal refinement. 
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3. Whether lasso and ridge regularisation are suitable techniques to 
enable the inclusion of a large number of potential interaction 
covariates. 
2. Materials and Methods 
2.1. Materials 
The longitudinal observational database used in this study is The Health 
Improvement Network (THIN) database (www.thin-uk.com). THIN contains 
complete medical records for patients registered at a participating general 
practice within the UK. At present approximately 6% of the UK general 
practices are participating, resulting in THIN containing data on over 4 
million active patients. The validity of the THIN database for 
pharmacoepidemiology studies has been investigated ? and it was shown 
that the data appear to be representative of the UK population. 
THIN contains time-stamped entries of drugs that are prescribed and 
medical events that the general practices are made aware of. Prescribed 
drugs are recorded with a British National Formulary (BNF) code indicating 
the family of the drug prescribed. Medical events are recorded using the Read 
coding system. The Read codes used in this study to identify myocardial 
infarction (MI) are available in Supplement A. 
The drug families (represented by BNF codes) investigated in this study 
are presented in Table 1 along with the ground truth (the known relationship 
between each drug family and MI), the number of prescriptions eligible for 
inclusion in the study and number of MI that occurred after an eligible 
prescription of each BNF. The ground truth relationship between these BNFs 
and MI are as specified in the Health Outcome of Interest (HOI) reference set 
used by the Observational Medical Outcomes Partnership (OMOP) ?. 
10 
Table 1: Summary of number of patients prescribed each drug family and number of patients 
who experience MI within 5 years of their first time prescription. 
Drug Family BNF+ No. First time 
prescriptions 
No. of MI* 
after BNF 
MI is a 
known ADR? 
Typical 
antipsychotics 
04020100 10061 44 Yes 
Benzodiazepines 04010200 74582 277 No 
Tricyclic 
antidepressants 
04030100 61384 221 Yes 
Antibiotics 1 05010300 78296 247 No 
Antibiotics 2 05010800 91515 258 No 
Bisphosphonates 06060200 8967 67 No 
Note: + BNF: British National Formula, * MI: Myocardial Infarction 
2.2. Analysis Methods 
2.2.1. Emergent Pattern Mining 
Emergent pattern mining is a type of association rule mining that aims to 
find differences between databases. Formally, let I = {i1,i2,,in} be the set of n 
items and t =⊂ X be a transaction containing a set of items. A database is a 
collection of transactions, denoted by D = {t1,t2,,tm}. The support of an itemset 
X in database D is the proportion of the database transactions that contain X, 
 SuppD(X) = |{ti ∈ D|X ⊂ ti}|/|D| (1) 
where |D| is the number of transaction in the database. An itemset is 
frequent if it has a support greater than some user defined minimum 
support 
value. 
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In the drug safety context, I represents the observational databases 
clinical vocabulary (e.g., International Classification of Diseases and 
RxNorm), and a patients transaction may correspond to the set of codes that 
they have recorded in the database during a specified time interval. An 
itemset is a collection of clinical vocabulary codes (e.g., {drug1, illness350, 
drug924}), and the support of the itemset is the fraction of the database’s 
patient transactions that contain the itemset. 
The idea of emergent pattern mining is to find itemsets that have a higher 
support in one database than others ?. A simple method for determining the 
emergent patterns is to find the itemsets that have a sufficiently high support 
in one of the databases and then calculate the lift, 
 lift(X) = SuppD1(X)/SuppD2(X) (2) 
However, this measure is vulnerable to volatility due to small support 
values and a bias-adjusted lift may be more suitable, 
 biaslift(X) = (SuppD1(X) + 1)/(SuppD2(X) + 1) (3) 
this measure adds a bias towards 1 when the support is low and is a common 
approach for dealing with rare events in drug safety[28]. 
2.2.1.1 Cox Regression 
Cox regression was chosen as this enables the consideration of the time to 
event (enabling long term effects to be evaluated) and the inclusion of 
rightcensored data. Using a method that ignores the time-to-event, such as 
logistic regression, would likely result in bias, as patients who leave the 
practice or die from alternative illnesses (right-censored patients) would not 
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be included into the analysis ?. The cox regression model assumes that the 
hazard at time t given the covariates x and baseline hazard is, 
 h(t|x) = h0(t)exp(Xxjβj) (4) 
j 
The parameter β is determined by maximising the partial likelihood ?. 
2.2.1.2 Regularised Cox Regression 
Regularisation is a technique to prevent models overfitting by adding a 
constraint to the complexity of the model. This is necessary when there are 
too many covariates in the model. In terms of cox regression, regularisation 
techniques add a constraint to the total size of the coefficients in the model. 
There are two main forms of regularisation penalty functions, ridge ? and 
lasso ?. The elastic net regularisation combines both the lasso and ridge 
penalty functions ?. Lasso regression is a regularised regression that adds a 
constraint to the total sum of the absolute value of the model coefficients into 
the optimisation, 
 λ||β||1 = λX|βj| (5) 
j 
This effectively causes some of the coefficients to disappear and is useful 
when there are a smaller number of medium or large effects. It has problems 
when there are correlations between covariates, as it will only pick one of the 
correlated covariates coefficients to be non-zero. Lasso regression has been 
used successfully with the aim of overcoming confounding in drug safety ? 
but no existing approach has included interactive terms. 
Ridge regression adds a constraint to the sum of the coefficients squared 
into the optimisation, 
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 λ||β||2 = λXβj2 (6) 
j 
this causes all the coefficients to shrink to zero as lambda tends to infinity. 
Ridge regression is useful if there are small effects, which may be the case for 
ADRs. Finally, the elastic net linearly combines both ridge and lasso 
regression penalties, 
 λ1||β||1 + λ2||β||2 = λ1 X|βj| + λ2 Xβj2 (7) 
 j j 
using the parameter α ∈ [0,1] = λ1/(λ1 + λ2). 
The regularised cox regression can be used to indicate the relative 
importance of each variable in determining the time-to-event of MI. If the 
drug suspected of causing MI is deemed to have a large coefficient by the 
regularised cox regression then this strengthens our suspicion, especially 
when alternative risk factors for developing MI are accounted for within the 
model. 
2.3. Method 
The proposed signal refinement methodology has two steps. Step 1 
involves applying emergent pattern mining to identify sets of medical 
conditions and medication that are risk factors for developing the outcome 
(candidate positive confounder interactions) or factors that reduce the 
likelihood of developing the outcome (candidate negative confounder 
interactions). Step 2 involves implementing a cohort study design and a risk 
adjusted multivariate analysis (e.g. regularised cox regression) with risk 
adjustment terms accounting for the candidate confounder variables 
identified in step 1. 
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2.3.1. Step 1 Candidate interactive confounder identification 
2.3.1.1 Select Data 
We imitated the data extraction of a case control study design to extract data 
for the emergent pattern mining. In this step we did not apply a case control 
design to investigate the effect of exposure, we just extracted the case control 
study design data for the emergent pattern mining. The cases are the patients 
who have the outcome recorded; their index date is the first time the 
outcome is recorded. Then two controls are selected for each case by 
matching on age (plus or minus 1 year), gender and general practice and 
finding the two patients that have the closest registration date to the case. 
We chose to match two controls per case as the majority of cases had two 
potential matches and the greater the number of controls, the more likely 
each itemsets support value will approximate the actual prevalence. Each 
control’s index date is the date of their matching cases index date. The 
exclusion criteria are: patients with a history of any of the exposures being 
investigated prior to index were excluded. Controls must have zero 
recordings of the outcome in the data. The inclusion criteria are: patients that 
are aged between 18 and 70 and patients must have been registered for at 
least a year prior to their index date. Figure 2 illustrates the implemented 
case control style design for extracting suitable data to apply emergent 
pattern mining to. The emergent pattern mining will find sets of 
drugs/medical conditions 
Table 2: Example of transactions found in D1 (the patients with the outcome recorded in the 
database) 
Patient Index Date General Sex Date of Medical transactions* 
ID (date of 
outcome) 
Practice Birth 
15 
1 01-02-2008 2 M 02-07-
1967 
Drug1, Drug110, Ill- 
ness1020, Illness15001 
15 23-01-2001 20 M 16-04-
1936 
Drug204,Drug110,Illness1020, 
llness3 
37 12-12-2001 1 F 
03-12-
1942 
Illness4 
... ... ... ... ... ... 
 
Note: * - All recorded prescriptions/medical items prior to index date 
that occur more often prior to index for the cases (those with the outcome, in 
our example MI) compared to the controls. These correspond to potential 
risk factors for the outcome. 
2.3.1.2 Create patients transaction baskets 
We then create two databases D1 and D2, see Tables 2-3. D1 contains the case 
patients medical transactions, i.e. the set of all medical events or drugs 
recorded prior to the index date for each patient in the case control study. D2 
contains the control patients medical transactions, i.e. the set of all medical 
conditions or drugs recorded prior to the index date. 
 3Control Patient 2 
3Control Patient 3 
3Control Patient 4 
7 Short Patient 5 
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Exposure 
3Control Patient 9 
... 
Figure 2: Step 1 study design illustration: For each patient in the longitudinal observational 
database we have their prescription timeline (dashed lines) and condition/observation 
timeline (straight line) since registration until they leave the practice or die. Circles 
represent recorded conditions and rectangles represent recorded medication. Each colour 
of the shape represents a type of drug or condition, for example a red rectangle represents 
MI. The patient’s timeline colour corresponds to their general prac-15 tice. The index date 
used for step 1, the first outcome record date, is represented by a dotted line. 
Table 3: Example of transactions found in D2 (the controls matched on practice, gender and age) 
Patient Index Date General Sex Date of Medical transactions* 
ID Practice Birth 
1020 01-02-2008 2 M 23-09-1967 Drug1, illness43,
 Illness2, 
Drug203 
1031 01-02-2008 2 M 01-05-1968 Illness3 
43 23-01-2001 20 M 08-02-1936 Illness3, Illness4010 
... ... ... ... ... ... 
Note: * - All recorded prescriptions/medical items prior to index date 
18 
2.3.1.3 Identify emergent patterns 
We then apply frequent itemset mining to D1 with a minimum support of 
0.001 to find all the cases’ frequent itemsets ID1 and apply frequent itemset 
mining to D2 with a minimum support of 0.0005 to find all the controls’ 
frequent itemsets ID2. The positive measure of interestingness is calculated 
by dividing the support of each itemset, X ∈ ID1, by its support in D2 but we 
add a bias to reduce the measure to one for small support values. For each X 
∈ ID1 we calculate, 
  if X ∈ ID1 ∩ ID2 
 D1  
 biasliftD2(X) = (SuppD1(X) + 1) if X ∈ ID1,X 6∈ ID2 (8) 
  0 otherwise 
The candidate positive confounding variables are the  
1}. The negative emergent patterns are found in a similar manner but we apply 
frequent itemset mining to D2 with a minimum support of 0.001 to find all the 
controls frequent itemsets ID2 and apply frequent itemset mining to D1 with a 
minimum support of 0.0005 to find all the cases frequent itemsets ID1. We then 
calculate ) and determine the candidate 
negative confounding variables as . 
For example, if we found that the itemset {Drug110,Illness1020} had a 
support of 0.05 in D1 (the itemset is found in the medical transactions for 
every 5 out of 100 patients with MI) and a support of 0.005 in D2 (the itemset 
is found in the medical transactions for every 5 out of 1000 control patients). 
Then {Drug110,Illness1020}) = 1.05/1.005 = 1.045 and would be 
considered a candidate positive confounding variable. 
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The minimum support value was a trade off between finding as many 
itemsets as possible and finding useful itemsets. The minimum support of 
0.001 means any identified itemset would be found in a minimum of 1 in 
1000 patients with MI. A support value less than 0.001 would likely find 
irrelevant itemsets, as they would be too rare to be useful. The support was 
reduced for the comparison database to increase the chance that the itemset 
is found in both databases frequent itemsets. 
Although it is possible to identify itemsets of any size using frequent 
itemset mining, in this paper we added a constraint to only find itemsets 
containing 5 items or less. This ensured the method was highly efficient and 
in general we found that itemsets containing more than 5 items often had 
small support values, so this constraint is unlikely to affect the results. 
Overall we were efficiently able to identify interactions containing up to 5 
variables that are associated with developing MI. We found 23808 variables 
recorded into THIN for patients who had MI recorded, this means we 
searched through 
Table 4: Example of the results of the emergent pattern mining. The most suitable variables are 
selected based on them having the greatest biaslift value. 
Itemset D1 Support D2 Support  
{Drug110,Illness1020} 0.05 0.005 1.045 0.957 
{Illness3, Illness4010} ¡0.0005 0.001 - 1.001 
{Drug201, Drug 104, 
Illness1023} 
0.0012 ¡0.0005 1.0012 - 
... ... ... ... ... 
6. , possible interactions to find the most common 
ones that are associated with developing myocardial infarction. 
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2.3.1.4 Select emergent patterns 
Table 4 displays the results of the emergent pattern mining approach (a list 
of sets of medical items that occur more for patients with/without the 
outcome). Finally we select the top k candidate positive confounding variable 
itemsets (with the greatest ) and the top k negative confounding 
variable itemsets (with the greatest ). These will be included into 
the cox regression using indicator variables to mark their presence or 
absence in each cohort patients medical history prior to their cohort index 
date. In this study we chose k = 200 as this seemed to give a sufficient number 
of candidate confounders while still enabling the methodology to be 
implemented 
efficiently. 
2.3.1.5 Justification 
The motivation for applying a case control study combined with emergent 
pattern mining is that we can find illnesses/drugs that are more common in 
the patients who have the exposure compared to those who never develop 
the exposure. These are the potential risk factors for the exposure, the first 
criterion necessary for a variable to be a confounder to the exposure- 
outcome relationship. By excluding patients from the case control data 
extraction who have the exposures being analysed, we are preventing the 
discovery of risk factors that are within the causal pathway between 
exposure and outcome (as this would violate the third criterion necessary for 
a variable to be a confounder). 
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2.3.2. Step 2 Cohort study with risk adjusted multivariate analysis 
2.3.2.1 Select Data 
We implement a cohort study design with a 5-year follow up period. For each 
drug family of interest being investigated, we find all the patients prescribed 
the drug family for the first time between the years 2005 and 2010 and set 
their index date as the first time prescription of the drug family. The inclusion 
criteria are: patients are aged between 18 and 65 at index (because we use a 
5 year follow up and the emergent patter mining was for patients aged 70 or 
younger) that have more than 1 years history prior to the index date. Figure 
3 illustrates the study design implemented in step 2, where each shade of 
blue circle corresponds to one of the exposures being investigated. If a 
patient was prescribed more than one of the exposures being investigated 
for the first time during 2005 and 2010, then they would be included multiple 
Table 5: Example of the results of the emergent pattern mining. The most suitable variables are 
selected based on them having the greatest biaslift value. 
PatientAge Sex Exposure1 ... ExposureN Itemset1 ... Itemset400 Outcome 
 (06060200) (04010200) 
2032 64 M 1 ... 1 0 ... 1 1 
10570 49 F 0 ... 0 0 ... 0 0 
34 58 M 1 ... 1 0 ... 0 1 
... ... ... ... ... ... ... ... ... ... 
times into the cohort but with different index dates, see patient 8 in Figure 
3. 
The covariates used in the cox regression model are the patients 
age/gender, indicator variables for each of the drug families being investigated 
(1 if the patient had a prescription of the drug family recorded prior to or on 
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the index date and 0 otherwise) and indicator variables for each of the 400 
candidate confounder itemsets identified in step 1 (1 if the patient has all items 
in the itemset recorded prior to index date and 0 otherwise). An example of 
the data used to learn the cox regression model is displayed in Table 5. 
2.3.2.2 Cox Regression Models 
We then implement various regularised cox regression models (using the 
elastic net regularisation detailed in equation 7 with various α ∈ [0,1] values 
including lasso:α = 1 and ridge:α = 0) using age/sex, drug family history 
indicators and candidate interaction confounders covariates. For 
comparison we also implement a standard cox regression model that only 
used the 
 Find first time 
... 
Figure 3: Step 2 study design illustration: For each patient in the longitudinal observational 
database we have their prescription timeline (dashed lines) and condition/observation 
timeline (straight line) since registration until they leave the practice or die. Circles 
represent recorded conditions and rectangles represent recorded medica21 
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tion. Each colour of the shape represents a type of drug or condition, for example a red 
rectangle represents MI and the different shades of blue circles represents the different 
exposures of interest. The patient’s timeline colour corresponds to their general practice and 
their gender is represented by gender symbols. 
age/sex and drug family indicator covariates. 
2.3.2.3 Validation 
Following standard computer science methodology we split the data into 
test/train sets. 50% of the data were used to train the cox regression models, 
as this was ample, and the remaining 50% of the data were used to validate 
the models. The summary time-dependant area under the receiver operating 
characteristic curve (AUC) ? was calculated to validate the model fit. 
2.3.2.4 Software 
The data were stored and manipulated in MS SQL Server and the analysis was 
conducted using the open source analysis language R ?. The frequent pattern 
mining was implemented using the arules package’s Apriori algorithm 
?, the standard cox regression was implemented using the survival package 
?, the regularised cox regression was implemented using the glmnet package 
? and the model validation was implemented using the survAUC package. 
3. Results 
3.1. Emergent pattern mining results 
We identified 77,246 eligible patients who had MI recorded and these 
patients transactions were included into D1. We matched 150,304 patients 
into D2. The frequent pattern mining was applied to 23,808 items in D1 and 
found 3,886,408 frequent itemsets for D1 with a minimum support of 0.001 
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(9920792 with a minimum support 0.0005). For D2 there were 26,705 items, 
with association rule mining identifying 2,092,949 frequent itemsets for D2 
with a minimum support of 0.001 (5,502,600 with a minimum support 
0.0005). In total we identified 3,838,643 potential candidate positive 
confounders and 57,507 potential negative confounders, however only the 
top 200 positive and top 200 negative candidate confounders were selected. 
One interesting observation of the emergent pattern mining results is that 
the there were more frequent itemsets discovered for the patients with MI 
compared to the control group in step 1. One explanation of this is that 
patients with MI are likely to be similar and share the common risk factors or 
MI preceding events, so the D1 dataset will be less sparse compared to D2, 
which consists of a more varied population. Another reason D2 is sparser is 
that it contained healthier (non-MI) patients, some of which may not have 
many items recorded. In future work it would be interesting to restrict D2 to 
patients with certain criteria, such as having a minimum number of items, 
and investigating how this effects the emergent patterns that are discovered. 
3.2. Cox regression results 
In total we used data for 162,889 patients for the cox regression analysis. 
The model concordance for the standard cox regression was 0.82 and none 
of the covariates violated the proportional hazard assumption. Table 6 
presents the ranking of the drug families based on the coefficient values 
obtained from a cox regression that only used the age/sex and drug family 
indicator covariates. The non-ADR bisphosphonates (BNF 06060200) was 
found to have the greatest hazard ratio. 
Table 7 presents the results of the elastic net regularised cox regression 
with the 6 drug families, age/sex and 400 candidate interactive confounders 
as covariates. The two known ADRs were correctly ranked above the non- 
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Table 6: Results of cox regression that does not include the candidate confounding interaction 
variables. 
 Rank Drug Family Coefficient Hazard Ratio (95% CI) Truth 
Covariate 
1 06060200 0.563 1.757 (1.326-2.326) Non-ADR 
2 04020100 0.398 1.488 (1.103-2.009) ADR 
3 04030100 0.255 1.291 (1.086-1.534) ADR 
4 05010300 0.150 1.162 (0.977-1.382) Non-ADR 
5 05010800 0.136 1.145 (0.958-1.369) Non-ADR 
6 04010200 0.069 1.071 (0.896-1.280) Non-ADR 
ADRs when candidate confounders were incorporated via a ridge cox regres- 
sion. 
On the 50% testing data the time dependant AUC for the standard cox 
regression was 0.816, the lasso regularised cox regression obtained an AUC 
of 0.825 and the ridge regularised cox regression obtained an AUC of 0.785, 
indicating strong model fits. 
4. Discussion 
This is the first methodology proposed for incorporating candidate 
interaction confounder covariates into a cox regression for drug safety. The 
standard cox regression that only considered indication of the various drug 
families on the day of or prior to index, age and sex ranked bisphosphonates 
(BNF 06060200), a non-ADR, as the most likely to cause MI. How- 
ever, incorporating the candidate interaction confounders into the elastic net 
regression with small values for α reduced the confounding in the analysis 
Table 7: The results of the elastic net cox regression. No. βs is the number of variables selected 
by the model. 
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Parameters 
α 1 (Lasso) 0.6 0.3 0.1 0.05 0 (Ridge)  
λ* 3.7×10−4 1.4×10−4 3.3×10−4 8.3×10−4 1.4×10−3 8.1×10−3  
No. βs 6 26  30 51 73 266  
   —   
Covariate   Coefficient values β (Rank)  Truth 
04030100 0 0.030 
(17) 
0.006 
(23) 
0.011 
(33) 
0.0123 
(38) 
0.0112 
(64) 
ADR 
04020100 0 0 0 0.003 
(38) 
0.011 
(41) 
0.011 
(67) 
ADR 
06060200 0 0.12 (6) 0.0152 
(21) 
0.012 
(30) 
0.0120 
(39) 
0.009 
(80) 
Non- 
ADR 
05010300 0 0 0 0 0 0.008 
(84) 
Non- 
ADR 
04010200 0 0 0 0 0 −7×10−4 
(166) 
Non- 
ADR 
05010800 0 0 0 -0.006 
(42) 
-0.022 
(66) 
-0.018 
(262) 
Non- 
ADR 
Note: 
-λ* is the maximum lambda that was within 1 standard deviation of the minimal 
cross-validation error as this was a trade off between maximising regularisation and 
minimising error. 
- Bold entries correspond to the top ranked drug family 
and correctly ranked the two known ADRs, tricyclic antidepressants (BNF 
04030100) and typical antipsychotics (BNF 04020100), above 
bisphosphonates. As α increased from 0 in the elastic net regression, the 
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framework was unable to reduce the confounding completely and still 
incorrectly ranked bisphosphonates as the most likely cause of MI. As α 
increased towards 1 (lasso regression), it was generally observed that the 
regularised regression did not identify any of the drug families as causes of 
MI, however, at certain small values of α (e.g., α = 0.1 ,α = 0.05), the lasso effect 
nicely filters some of the non-MI causing drug families, although 
bisphosphonates were still ranked above some of the known ADRs. This 
shows that elastic net cox regression including the candidate interactive 
confounders has the potential to not only re-rank ADRs signals, but also filter 
the false positive signals. The results suggest the ideal ADR signal refinement 
framework should take a multiple step approach and combine results 
obtained with various values of α. For example, use elastic net cox regression 
with a small α to filter signals firstly and then use elastic net cox regression 
with α set to zero to rank the remaining signals. 
One possible reason why the elastic net cox regression with α = 0 was able 
to correctly rank the drug families is that it incorporated more covariates into 
the model, even those with small effects. The result that the elastic net cox 
regression with a small α was better than lasso regression, also provides 
some evidence that the candidate interactive confounder covariates are 
appropriate, as including them into the cox regression reduced confounding. 
The fact that lasso regression shrunk all the drug families coefficients to zero 
is not unexpected, as lasso regression identifies large/medium effects, but 
ADRs that are difficult to distinguish from confounding are likely to have a 
small effect size. This suggests that the choice of α will depend on the 
outcome being investigated (e.g., is it common/rare) and the relationship 
between the drugs and outcome. Rather than relying on the results obtained 
by picking the optimal lambda for lasso regression, it may be suitable to 
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investigate the results returned for a range of lambdas and identify the order 
in which the drug family variables are entered into the regularised models as 
the regularisation decreases. The last n occurring drug family variables (or 
those with negative coefficients) could then be filtered out. Another possible 
explanation for elastic net cox regression with α = 0 outperforming lasso is 
due to unmeasured confounding. If there are many unmeasured confounders, 
then adding more candidate interaction confounder covariates may increase 
the chance of identifying a proxy variable for some unmeasured confounding. 
Therefore, as elastic net cox regression with a small α includes more 
covariates it will have an advantage over lasso regression, as it is may 
overcome some unmeasured confounding. 
We purposely chose MI in this study as the outcome of interest due to it 
having a high background rate, so confounding is a common issue, and also 
due to missing data problems being common (MI may only be recorded in 
secondary care and missed from the primary care record). For example, some 
patients experiencing a MI may not have the event recorded in their primary 
care records as they may go to hospital. Hospitalisation may also cause the 
recording date to be incorrect in THIN. By purposely choosing a difficult 
outcome, we are testing whether the proposed method can overcome both 
confounding and data recording issues. However, the proposed method does 
require that the patients have medical histories; otherwise it would not be 
possible to identify confounders related to outcome progression. This may 
limit which databases the methodology can be applied to, as longitudinal 
observational data with short observation periods are less suitable, although 
even a short period of history may be useful for reducing confounding. 
Therefore, it would be useful in future research to determine whether the 
proposed method can successfully reduce confounding when applied to other 
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outcomes or when implemented for signal refinement using other 
longitudinal observational data. 
Overall the methodology shows promise at refining ADRs by reducing 
confounding. The results show that combining emergent pattern mining and 
elastic net cox regression is an effective and efficient data-driven framework 
for reducing the issue of confounding that is common in longitudinal 
observational studies. However, further research is required to identify: 
• The optimal value for k (the number of candidate confounder covari- 
ates) 
• The most suitable choice of α for the elastic net (or combination) 
• The types of outcomes that are suitable for the method (e.g., common, 
rare, progressive, chronic, acute) 
The proposed methodology has the advantage of being efficient as it is 
datadriven, it is applicable for analysing both short-term and long-term ADRs 
and it can remove false ADR signals. However, formal epidemiology study 
designs will still need to be applied to the unfiltered signals before causality 
can be established. 
5. Conclusions 
In this paper we proposed a novel framework to efficiently enable the 
inclusion of high-order interactive terms, potentially representing 
confounders, into a cox regression analysis to refine ADR signals. The 
framework combines emergent pattern mining, that searches billions of 
possible interactions to identify terms potentially corresponding to 
confounders, and regularised cox regression. We investigated the framework 
by applying it to investigate how likely six different drug families are to cause 
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MI. The drug families were chosen as they are from a reference set developed 
to evaluate ADR signal detection methods and there have been numerous 
studies investigating their relationships with MI. A standard cox regression 
only considering the risk adjustments of age, sex and indicators for the five 
drug families was shown to be negatively effected by confounding. However, 
our proposed automated framework for incorporating candidate confounder 
interaction terms into an elastic net cox regression was shown to be more 
resilient to confounding and correctly ranked the drug families in order of 
how likely they are to cause MI. This shows excellent potential for reducing 
the current high false positive rate issue when using longitudinal 
observational data for drug safety. 
In future work the framework’s robustness should be tested by 
implementing the framework to refine ADR signals for alternative outcomes 
or by using alternative longitudinal observational data. 
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